Literature DB >> 19223548

Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.

Trisha M Wise-Draper1, Rachael A Mintz-Cole, Teresa A Morris, David S Simpson, Kathryn A Wikenheiser-Brokamp, Mark A Currier, Timothy P Cripe, Gerard C Grosveld, Susanne I Wells.   

Abstract

High levels of expression of the human DEK gene have been correlated with numerous human malignancies. Intracellular DEK functions have been described in vitro and include DNA supercoiling, DNA replication, RNA splicing, and transcription. We have shown that DEK also suppresses cellular senescence, apoptosis, and differentiation, thus promoting cell growth and survival in monolayer and organotypic epithelial raft models. Such functions are likely to contribute to cancer, but direct evidence to implicate DEK as an oncogene has remained elusive. Here, we show that in line with an early role in tumorigenesis, murine papilloma formation in a classical chemical carcinogenesis model was reduced in DEK knockout mice. Additionally, human papillomavirus E6/E7, hRas, and DEK cooperated in the transformation of keratinocytes in soft agar and xenograft establishment, thus also implicating DEK in tumor promotion at later stages. Finally, adenoviral DEK depletion via short hairpin RNA expression resulted in cell death in human tumor cells in vitro and in vivo, but did not significantly affect differentiated epithelial cells. Taken together, our data uncover oncogenic DEK activities as postulated from its frequent up-regulation in human malignancies, and suggest that the targeted suppression of DEK may become a strategic approach to the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223548      PMCID: PMC2650744          DOI: 10.1158/0008-5472.CAN-08-2304

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS.

Authors:  B L Allen-Hoffmann; S J Schlosser; C A Ivarie; C A Sattler; L F Meisner; S L O'Connor
Journal:  J Invest Dermatol       Date:  2000-03       Impact factor: 8.551

2.  The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner.

Authors:  V Alexiadis; T Waldmann; J Andersen; M Mann; R Knippers; C Gruss
Journal:  Genes Dev       Date:  2000-06-01       Impact factor: 11.361

3.  Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes.

Authors:  A M Helt; D A Galloway
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Subcellular localization of the human proto-oncogene protein DEK.

Authors:  F Kappes; K Burger; M Baack; F O Fackelmayer; C Gruss
Journal:  J Biol Chem       Date:  2001-05-01       Impact factor: 5.157

Review 5.  Signal transduction pathways controlling the switch between keratinocyte growth and differentiation.

Authors:  G P Dotto
Journal:  Crit Rev Oral Biol Med       Date:  1999

6.  Protein phosphatase 2A activates the HIV-2 promoter through enhancer elements that include the pets site.

Authors:  N E Faulkner; J M Hilfinger; D M Markovitz
Journal:  J Biol Chem       Date:  2001-04-24       Impact factor: 5.157

7.  Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.

Authors:  P J Reddig; N E Dreckschmidt; H Ahrens; R Simsiman; C P Tseng; J Zou; T D Oberley; A K Verma
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

8.  Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy.

Authors:  H Klump; B Schiedlmeier; B Vogt; M Ryan; W Ostertag; C Baum
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

9.  DEK proto-oncogene expression interferes with the normal epithelial differentiation program.

Authors:  Trisha M Wise-Draper; Richard J Morreale; Teresa A Morris; Rachael A Mintz-Cole; Elizabeth E Hoskins; Scott J Balsitis; Nader Husseinzadeh; David P Witte; Kathryn A Wikenheiser-Brokamp; Paul F Lambert; Susanne I Wells
Journal:  Am J Pathol       Date:  2008-11-26       Impact factor: 4.307

10.  The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon-product complexes.

Authors:  T McGarvey; E Rosonina; S McCracken; Q Li; R Arnaout; E Mientjes; J A Nickerson; D Awrey; J Greenblatt; G Grosveld; B J Blencowe
Journal:  J Cell Biol       Date:  2000-07-24       Impact factor: 10.539

View more
  54 in total

Review 1.  Histone-modifying enzymes, histone modifications and histone chaperones in nucleosome assembly: Lessons learned from Rtt109 histone acetyltransferases.

Authors:  Jayme L Dahlin; Xiaoyue Chen; Michael A Walters; Zhiguo Zhang
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-11-03       Impact factor: 8.250

2.  External Qi of Yan Xin Qigong induces cell death and gene expression alterations promoting apoptosis and inhibiting proliferation, migration and glucose metabolism in small-cell lung cancer cells.

Authors:  Xin Yan; Feng Li; Igor Dozmorov; Mark Barton Frank; Ming Dao; Michael Centola; Wei Cao; Dan Hu
Journal:  Mol Cell Biochem       Date:  2011-12-10       Impact factor: 3.396

Review 3.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 4.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

5.  DEK regulates hematopoietic stem engraftment and progenitor cell proliferation.

Authors:  Hal E Broxmeyer; Ferdinand Kappes; Nirit Mor-Vaknin; Maureen Legendre; John Kinzfogl; Scott Cooper; Giao Hangoc; David M Markovitz
Journal:  Stem Cells Dev       Date:  2011-10-27       Impact factor: 3.272

6.  The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress.

Authors:  A Deutzmann; M Ganz; F Schönenberger; J Vervoorts; F Kappes; E Ferrando-May
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

7.  Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Authors:  Dong-Mei Wang; Ling Liu; Lei Fan; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2012-10-10       Impact factor: 4.742

Review 8.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 9.  Histone chaperones in nucleosome assembly and human disease.

Authors:  Rebecca J Burgess; Zhiguo Zhang
Journal:  Nat Struct Mol Biol       Date:  2013-01       Impact factor: 15.369

10.  Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma.

Authors:  Yingfu Ou; Rongjun Xia; Fanyong Kong; Xiaokang Zhang; Shengjin Yu; Lili Jiang; Linlin Zheng; Lijuan Lin
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.